Study from Johns Hopkins Kimmel Cancer Center reveals immune signatures predict immunotherapy side effects.

A study from Johns Hopkins Kimmel Cancer Center reveals that specific immune signatures in cancer patients undergoing immunotherapy can predict adverse side effects. Researchers found that increases in T-cell helper 2 (Th2) and T-cell helper 17 (Th17) white blood cells, along with rising interleukin-6 (IL-6) levels, indicate higher risks for these events. The findings aim to help oncologists identify high-risk patients early and improve treatment outcomes through targeted therapies.

October 15, 2024
6 Articles

Further Reading